Reduced cytotoxic T-lymphocyte antigen 4 (CTLA4) expression has been proposed as a risk for autoimmunity. CTLA4 polymorphisms have been associated with several autoimmune diseases, including ulcerative colitis (UC). In this study, we performed genotyping for CTLA4 À1661A/G, À1722T/C and 3 0 untranslated region (AT)n repeat polymorphisms in 300 Chinese UC patients and in 700 healthy controls, and evaluated the effects of polymorphisms on full-length (flCTLA4) and soluble CTLA4 (sCTLA4) expression in UC patients. The frequency of the À1661G allele was higher in UC patients than in healthy controls (16.5 vs 11.4%, P ¼ 0.003, odds ratio (OR) ¼ 1.53, 95% confidence interval (95% CI): 1.17-2.01). The prevalence of (AT)n repeats of the CTLA4 gene carrying long alleles (X116 bp) was more common in UC patients than in healthy controls (22.0 vs 6.3%, Po0.001, OR ¼ 4.21, 95% CI: 2.79-6.33), and was associated with extensive colitis (P ¼ 0.008). Among UC patients, long-allele carriers expressed lower levels of flCTLA4 and sCTLA4 mRNA and sCTLA4 protein than did short-allele carriers (Po0.001, Po0.001, Po0.001, respectively). CTLA4 gene À1661A/G and long 3 0 untranslated region (AT)n repeat polymorphisms are associated with UC in Central China. This is likely from decreased expressions of sCTLA4 mRNA and sCTLA4 protein. Our study suggests that CTLA4 has an important role in susceptibility for UC in Central China.
Introduction
Inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), is characterized by chronic inflammation of the gastrointestinal tract, of unknown etiology. The prevalence of UC has increased in China;
1 the exact causes of this increase remain unknown.
Over the past two decades, numerous studies have been performed to identify genetic risk factors for UC. Polymorphisms of human leukocyte antigen, particularly human leukocyte antigen class II alleles DRB1*1502 in populations of Asian and European ancestry and DRB1*0103 in populations of European ancestry, were the first consistent UC risk polymorphisms identified. 2 Recent genome-wide association studies (GWAS) in both UC and CD have established multiple genes and loci as UC risk factors. TNFSF15 (tumor necrosis factor receptor superfamily 15), identified in the first CD GWAS in the Japanese population, was shown to be associated with an increased risk for UC and CD in a British study. 3 The first European ancestry CD GWAS identified the interleukin 23 receptor ligand as a significant risk gene for both UC and CD. The first nonsynonymous single-nucleotide polymorphism scan in UC found genome-wide association with extracellular matrix 1 on chromosome 1q21. 4 GWAS meta-analyses in CD have established more than 30 loci, and several of these loci have also been found to be associated with UC. For example, in a European study, Franke et al. 5 reported the association between UC and CD loci, including 3p21.31, NKX2-3 and CCNY. A European UC GWAS found significant evidence for association with interleukin (IL) 10, 6 and a North American UC GWAS found associations with chromosomes 1p36 (near the PLA2G2E gene) and 12q15 (IL22). 7 Finally, a recent pediatric inflammatory bowel disease GWAS found TNFRSF6B and PSMG1 to be highly significant genes for both UC and CD. 8 Associations of other candidate genes from previous studies such as MDR1 (also known as ABCB1), and Toll-like receptor 4 with inflammatory bowel disease have been found in some, but not all populations. 9, 10 These studies indicate complex polygenic associations for UC, and highlight immune-related genes as important to UC etiopathogenesis.
It is accepted that the inflammatory response in UC results from T-cell-mediated immunity to bacterial antigens in genetically susceptible hosts; the histological hallmarks of UC include a dense infiltrate of lymphocytes and macrophages. 11 Hence, T-cell immunity has a pivotal role in the pathogenesis of intestinal inflammation in UC.
Cytotoxic T-lymphocyte antigen 4 (CTLA4) is an immunoregulatory molecule, which is involved in the negative regulation of T-cell proliferation. 12, 13 The CTLA4 gene produces two different isoforms: a full-length CTLA4 (flCTLA4) protein, encoded by exon 1 (peptide leader), exon 2 (extracellular domain), exon 3 (transmembrane domain) and exon 4 (cytoplasmic domain), as well as a soluble CTLA4 (sCTLA4) protein in which exon 3 is lost. The flCTLA4 protein is expressed mainly in activated T cells, whereas the sCTLA4 protein is secreted mainly by resting T cells, and sCTLA4 mRNA expression is downregulated after activation.
14, 15 The lack of CTLA4 in knockout mice causes important lymphoproliferative disorders, multiorgan destruction and premature death. 16 Moreover, CTLA4 small interfering RNA knockdown in animals leads to the development of autoimmune diabetes. 17 Hence, CTLA4 is involved in resistance to the inflammatory response, and it has been suggested that CTLA4, which is an important negative regulator of T cells, might be implicated in the pathogenesis of T-cell-mediated UC. 11, 13 CTLA4 is involved in susceptibility to autoimmune diseases. 18, 19 Several single-nucleotide polymorphisms have been associated with autoimmune diseases such as type I diabetes, Graves' disease (GD) and multiple sclerosis; however, some of these associations have not been confirmed, and there are even some contradictory data in different populations. [20] [21] [22] Interestingly, CTLA4 À1722T/C and À1661A/G polymorphisms, both located in the promoter region, were found to be associated with GD 21 and celiac disease, 23 respectively. Celiac disease has been observed more frequently in patients with UC, and genetic connections between celiac disease and UC have also been demonstrated in IL2 and IL21 genes, which are associated with celiac disease in a GWAS; 24 moreover, Festen et al. 25 found strong association for these same genes and UC.
Recently, (AT)n repeats in the CTLA4 gene have become a focus of research in autoimmune diseases. 21, [26] [27] [28] Allelic variation in the (AT)n repeat polymorphism, located in the 3 0 untranslated region (3 0 UTR) of exon 4 of the CTLA4 gene, was shown to be correlated with CTLA4 mRNA expression. In patients with myasthenia gravis, Wang et al. 29 found that longer (AT)n repeat alleles had significantly lower CTLA4 mRNA expression than did shorter alleles; the relative amounts of CTLA4 mRNA from individuals carrying longer (AT)n repeat alleles decreased more quickly than did that of individuals carrying shorter alleles.
Despite the promising role of the CTLA4 gene, there are very few studies that have assessed its role in UC patients, and the functional implications of the CTLA4 gene polymorphisms for UC have not been established. In this study, we conducted a systematic analysis to establish the role of CTLA4 polymorphisms in UC, and their effects on the CTLA4 gene and protein expression.
We present herein a large and detailed genotypephenotype analysis of the CTLA4 À1661A/G, À1722T/ C and (AT)n repeat polymorphisms in an independent cohort of confirmed UC cases and healthy controls, and studied their effects on flCTLA4 and sCTLA4 mRNA and protein expression in UC patients in Central China.
Results
Distribution of CTLA4 allele and genotype frequencies in patients with UC and in healthy controls In all subjects, genotype distributions were in HardyWeinberg equilibrium for the À1661A/G (P ¼ 0.625 in UC and P ¼ 0.241 in controls), À1722T/C (P ¼ 0.303 in UC and P ¼ 0.059 in controls) or (AT)n repeat polymorphisms (P40.05 in UC and P40.05 in controls). The sex ratio and distribution of age did not differ between UC patients and healthy controls (P ¼ 0.889, P ¼ 0.206, respectively). The distribution of À1661A/G and À1722T/C allele and genotype frequencies in patients with UC and in healthy controls are shown in Table 1 . The frequencies of the G allele and the G carrier of À1661A/G were significantly higher in UC patients than in healthy controls (16.5 vs 11.4%, P ¼ 0.003, odds ratio (OR) ¼ 1.53, 95% confidence interval (95% CI): 1.17-2.01; 30.7 vs 22.0%, P ¼ 0.004, OR ¼ 1.57, 95% CI: 1.16-2.13, respectively). The distribution of À1722T/C allele and genotype frequencies did not differ between UC patients and healthy controls.
The distribution of allele and genotype frequencies of (AT)n repeats of the CTLA4 gene in patients with UC and in healthy controls is shown in Table 2 . A total of 22 microsatellite alleles were detected in the Chinese Han population. The allele frequencies of 120 and 122 bp fragments were significantly increased in UC patients compared with healthy controls (2.3 vs 0.5%, P ¼ 0.001, We investigated the disease-associated variants in CTLA4 (AT)n repeats and À1661A/G for statistical interaction with respect to UC disease risk. The frequencies and ORs of individual À1661A/G risk genotypes were stratified by CTLA4 (AT)n repeat genotypes. On the background of the À1661A/G high-risk genotype 'AG þ GG', carriers of (AT)n long alleles were associated with a relatively higher risk of UC compared with controls, with an OR of 10.60 (95% CI: 3.00-37.49), whereas on the background of the À1661A/G low-risk genotype AA, carriers of (AT)n long alleles also showed a significant but more modest risk of UC compared with controls, with an OR of 3.90 (95% CI: 2.49-6.11).
The association of CTLA4 gene polymorphisms with the risk of UC was estimated by logistic regression analysis using a model that included age, sex and the polymorphisms of À1661A/G and (AT)n repeats of the CTLA4 gene. As shown in Table 3 , we found that the carrier of (AT)n long alleles was a significant independent risk factor of UC, with an OR of 4.47 (Po0.001, 95% CI: 2.95-6.78).
Association of the CTLA4 genotype with extent of disease and extraintestinal manifestations in UC patients The association of CTLA4 gene polymorphisms with the extent of disease and extraintestinal manifestations of UC patients is shown in Table 4 . The (AT)n repeats carrying long alleles showed no association with extraintestinal manifestations in UC patients, but there was a significant association of the (AT)n repeats carrying long alleles with more extensive colitis disease among UC patients (32.6 vs 17.8%, P ¼ 0.008, P c ¼ 0.024, OR ¼ 2.24, 95% CI: 1.26-3.96). Both À1661A/G and À1722T/C polymorphisms were not associated with the extent of disease or with extraintestinal manifestations in UC patients.
CTLA4 mRNA expression in UC patients and in healthy controls As illustrated in Figure 1 , flCTLA4 and sCTLA4 mRNA expression levels were decreased in biopsies of inflamed colonic tissue obtained from UC patients (n ¼ 48) compared with that of healthy controls (n ¼ 12) (P ¼ 0.032, P ¼ 0.005, respectively). Among UC patients, sCTLA4 mRNA expression levels were decreased in biopsies of inflamed colonic tissue (n ¼ 48) compared with noninflamed tissue (n ¼ 15) (P ¼ 0.004); there was no difference in flCTLA4 mRNA expression levels between biopsies of inflamed colonic tissue and noninflamed tissue (P ¼ 0.192). There was no difference in flCTLA4 mRNA and sCTLA4 CTLA4 (AT)n repeats carrying long alleles correlate with the expression of flCTLA4 and sCTLA4 mRNA in intestinal mucosa As a significant association was observed between CTLA4 (AT)n repeats carrying long alleles and the extent of disease in UC patients, quantitative PCR experiments were conducted to determine flCTLA4 and sCTLA4 mRNA expression levels in UC patients for individuals carrying both long and short alleles. Patients carrying long alleles (n ¼ 4) expressed slightly lower levels of flCTLA4 and sCTLA4 mRNA in noninflamed colonic biopsies than did those carrying short alleles (n ¼ 11) (P ¼ 0.006, P ¼ 0.007, respectively; Figure 2a ). The effect of polymorphisms on flCTLA4 and sCTLA4 mRNA expression was more significant in inflamed colonic biopsies than in noninflamed tissue. Patients carrying long alleles (n ¼ 14) expressed significantly lower levels of flCTLA4 and sCTLA4 mRNA in inflamed colonic tissue than did those carrying short alleles (n ¼ 34) (Po0.001, Po0.001, respectively; Figure 2b ). In healthy controls, there was no difference in flCTLA4 and sCTLA4 mRNA expression levels between the carrier of the long alleles of (AT)n repeats (n ¼ 4) and the carrier of short alleles (n ¼ 8) (P ¼ 0.109, P ¼ 0.124, respectively; Figure 2c ). However, there was a tendency toward lower values in healthy controls for individuals carrying long alleles compared with those carrying short alleles.
The length of CTLA4 (AT)n repeats was negatively correlated with the stability of CTLA4 mRNA To determine the reason for this difference in expression levels of CTLA4 mRNA from individuals carrying long alleles and short alleles, the half-life (t 1/2 ) of CTLA4 mRNA was analyzed in patients with UC. Peripheral blood mononuclear cells (PBMCs) were incubated with actinomycin D to inhibit transcription. The levels of CTLA4 mRNA were measured by quantitative PCR. The flCTLA4 and sCTLA4 mRNA with long (AT)n repeat alleles (n ¼ 8) have a shorter half-life than does mRNA with short (AT)n repeat alleles (n ¼ 8), as shown in Figure 3 , in which a graph of mRNA activity vs time demonstrates a steeper slope, and hence, a shorter halflife for mRNA with long (AT)n repeat alleles. Figure 1 Relative expression levels of flCTLA4 (a) and sCTLA4 mRNA (b) in biopsies of inflamed and noninflamed colonic tissues obtained from UC patients, and colonic biopsies from healthy controls (HC), using arbitrary units. CTLA4 mRNA expression levels were normalized to the expression in healthy controls in which CTLA4 mRNA expression levels were set arbitrary as 1. Association between CTLA4 (AT)n repeats carrying long alleles, and flCTLA4 and sCTLA4 protein We found that patients carrying long alleles (n ¼ 14) expressed lower levels of sCTLA4 protein in their sera during active disease than did those carrying short alleles (n ¼ 34) (Po0.001; Figure 4 ). In the inflamed colonic tissue of UC patients, immunostaining for the flCTLA4 protein was mainly expressed in T cell and macrophage (membrane and intracellular). Brown color staining was considered as a positive expression for the flCTLA4 protein. Integral optical density analysis was performed to assess differences in staining intensity for the flCTLA4 protein. The mean optical density did not differ between the carrier of long alleles of (AT)n repeats (n ¼ 14) and short alleles (n ¼ 34) (0.19 ± 0.04 vs 0.20±0.01, P ¼ 0.227; Figure 5 ). 
Discussion
This study provides strong evidence for the association between the CTLA4 long microsatellite polymorphism and UC in the Han Chinese in Central China. We further found that (AT)n repeats carrying long alleles were predictors for extensive colitis among UC patients. As extensive colitis is considered a more severe phenotype with higher rates of colectomy and dysplasia or colorectal cancer, this finding provides additional support for the long (AT)n repeats as risk factors for greater inflammation driving UC. We also identified a novel risk allele, CTLA4 À1661A/G, which was associated with UC in our study. It is interesting that we found the increased OR value with the G carrier of À1661A/G and the (AT)n repeats carrying long alleles, relative to the AA genotype and the (AT)n repeats carrying long alleles. However, the 95% CIs were wide, and larger studies will be required to determine the exact nature of the statistical interaction between CTLA4 (AT)n repeats and À1661A/G variants.
The confirmation of a CTLA4 variant as an independent risk factor for UC gives further support for a major role of CTLA4 as an inherited risk factor for multiple diseases of immune dysregulation. With an increased incidence of celiac disease in UC patients, and with a genetic link between the two diseases demonstrated in coassociation of IL2 and IL21, 24, 25 it is interesting that both celiac disease and UC in our study were associated with the CTLA4 À1661A/G polymorphism. 23 It will be interesting to see whether CTLA4 long (AT)n repeats are similarly associated with celiac disease, and also whether patients concordant for both celiac disease and UC are especially likely to have these CTLA4 risk alleles.
We have previously reported the association of CTLA4 long (AT)n repeat alleles with UC in a small sample by nondenaturing PAGE. 27 This study shows an association between CTLA4 long (AT)n repeat alleles and UC in the Han Chinese in Central China in a much larger sample consisting of an entirely new cohort of UC patients and healthy controls. This association was demonstrated by a semi-automatic fluorescently labeled PCR method, based on capillary electrophoresis combined with fluorescence detection, which could offer high-resolution separation, high reproducibility and high sensitivity for measuring microsatellite allele sizes, providing size accuracy within 1 bp of the actual size. 30, 31 The distribution of allele frequencies in healthy controls in this study was similar to that of the previous study. There was a difference of B2 bp in the length of the PCR product compared with that of the previous study, which is probably because of the different methods used. The most consistent correlation of the allele sizes from this study is that the alleles are 2 bp shorter than the corresponding alleles from the original study (the most common allele is 84 bp in this study and 86 bp in our previous cohort using the PAGE genotyping method). This problem of small differences in the microsatellite allele when determined on different genotyping platforms is well established. [32] [33] [34] For this study cohort, alleles of 116 bp and larger were classified as the long-allele group (consistent with the previous analysis of 118 bp and larger alleles classified as the longallele group) and those shorter than 116 bp as the shortallele group.
A family-based study found a strong association of the CTLA4 (AT)n repeat polymorphism with GD in the Han population of Taiwan, 21 and revealed that (AT)n repeat polymorphisms represented an independent signal to the risk of GD. Slavcheva et al. 35 found that long alleles of (AT)n repeats of the CTLA4 gene were associated with an increased risk of acute rejection. It has been suggested that the frequency of long alleles of (AT)n repeats was increased among patients with Wegener's granulomatosis. 28 Machida et al. 36 classified (AT) 7 repeat alleles as a short-allele group and 4(AT) 7 repeat alleles as a long-allele group, and found an increase in long alleles of (AT)n repeats in UC patients; however, the difference was not statistically significant. This discrepancy might be explained by the different classification of long alleles for the (AT)n repeat fragments as well as limited power, or by ethnicity or gene-environment interactions present in Central China but not in Japan.
Our group has tested the CTLA4 reporter gene construct using site-directed PCR-based mutagenesis, and has observed no significant differences in luciferase activity between the A and G alleles at position À1661 promoter variants of the CTLA4 gene (8.62 ± 0.37 vs 8.07±0.71, P40.05; Chun Li, Bing Xia, Zhitao Chen Ting Jiang, unpublished data). Chistiakov et al. 37 also found no significant impact of the CTLA4 À1661A/G polymorphism on luciferase activity, although the polymorphism was associated with GD. Wang et al. 38 found no differences in CTLA4 expression levels between different alleles and genotypes of the CTLA4 À1661A/G Figure 5 Representative results of immunostaining of flCTLA4 protein (arrow) in biopsies of inflamed colonic tissue from UC patients for individuals carrying long alleles (a) and short alleles (b) of the (AT)n repeat polymorphism.
CTLA4 gene polymorphisms in UC
Z Chen et al polymorphism in myasthenia gravis patients, although a transcription factor binding site (c/EBPb) at position À1661 of the CTLA4 gene is predicted in the presence of the G allele rather than the A allele, as demonstrated using chromatin immunoprecipitation and electrophoretic mobility shift assay. It has been reported that five single-nucleotide polymorphisms of the CTLA4 gene (namely À1661A/G, À658C/T, À318C/T, þ 49A/G and þ 6230A/G) are in strong linkage disequilibrium. 39 The CTLA4 À318C/T polymorphism could affect transcriptional efficiency by modifying a transcription factor binding site for LEF1, and thereby regulate CTLA4 expression. 39 Ueda et al. 40 found lower CTLA4 expression levels from the G allele at the þ 6230A/G polymorphism. Hence, the CTLA4 À1661A/G polymorphism, could be associated with UC and effect gene expression as part of a haplotype with combined effects of neighboring polymorphic markers, such as À318C/T or þ 6230A/G.
Our data have shown lower levels of flCTLA4 and sCTLA4 mRNA in biopsies of inflamed colonic tissue obtained from UC patients. Our findings are similar with those of several recent reports, which showed that the flCTLA4 protein and sCTLA4 mRNA levels were decreased in myasthenia gravis patients, 29, 41 and sCTLA4 protein levels were decreased in individuals with diabetes, Behcet's disease and abdominal aortic aneurysm; [42] [43] [44] however, Wong et al. 45 have shown increased levels of the sCTLA4 protein in systemic lupus erythematosus. Possible mechanisms producing different levels of sCTLA4 levels in autoimmune diseases could be: (1) stimulation of T lymphocytes results in significantly decreased expression of sCTLA4, 15 (2) there are cell types other than T cells expressing CTLA4, for example, skeletal muscle cells and granulocytes, 46, 47 which also may express sCTLA4 and secrete into serum, (3) protein levels are affected not only by mRNA levels; and (4) differential sCTLA4 levels may correlate with different CTLA4 genotypes, disease types and immunological states. All of these mechanisms support a relationship between expression of CTLA4 and autoimmune diseases.
The CTLA4 (AT)n repeats have been well studied for an association between gene polymorphisms and autoimmune diseases, but the functional consequences of the polymorphism of CTLA4 (AT)n repeats in relation to UC are unknown. Our results support the hypothesis that the polymorphism of (AT)n repeats influences CTLA4 expression. Individuals with UC who have long alleles expressed lower levels of flCTLA4, and especially sCTLA4 mRNA, in fresh biopsies. They also had lower sCTLA4 protein levels in serum compared with subjects who had short alleles. The effects of (AT)n repeat polymorphisms on flCTLA4 and sCTLA4 mRNA expression were more remarkable in biopsies of inflamed colonic tissue than in noninflamed tissue of patients with UC, thus providing additional support for the observation that CTLA4 expression levels are influenced at the transcriptional level in a genotype-dependent manner, and are correlated with disease status.
Our study showed that mRNA with long (AT)n repeat alleles has a shorter half-life and, hence, is more unstable. Therefore, long (AT)n repeat alleles contributed to decreased mRNA stability. Our findings corroborate those of Wang et al. 29 in myasthenia gravis. Longer (AT)n repeat alleles contributed to reduced expression of CTLA4 mRNA; RNA degradation tests indicated that the length of CTLA4 (AT)n repeats was negatively correlated with the stability of CTLA4 mRNA. Thus, the (AT)n repeat polymorphism in the 3 0 untranslated region affects mRNA stability, and may also affect splicing of the alternative CTLA4 transcripts. 29 The CTLA4 (AT)n repeats are not anonymous repeat polymorphisms found within the CTLA4 region, but are located within the 3 0 untranslated region, and perhaps have an effect on the steady-states levels of CTLA4 mRNA. In support of this hypothesis, Malquori et al. 26 have shown that long (AT)n repeats of CTLA4 downregulate firefly luciferase reporter gene expression and CTLA4 protein expression levels in vitro. It has been shown that long alleles of (AT)n repeats may contribute to the disease status by influencing T-cell reactivity either by affecting mRNA expression levels or by disrupting a phosphorylation signal in this region of the gene. 48 In addition, the CTLA4 (AT)n repeat polymorphism also has been shown to alter the inhibitory function of the protein wherein long alleles of (AT)n repeats were associated with reduced control of T-cell proliferation in patients with GD. 49 The importance of CTLA4 in the counter-regulation of CD28 T-cell antigen receptor activation of T cells is well established.
12,13 sCTLA4 can bind CD80/86 molecules, block the B7-CD28 interaction and interfere with the costimulation signal, inhibiting T-cell proliferation in vitro.
14,15 sCTLA4 mRNA levels are negatively associated with a CTLA4 disease-susceptibility genotype. 40, 50 We found that (AT)n repeats of the CTLA4 gene carrying long alleles were more frequent among UC patients, We also found that individuals with UC who carry long alleles expressed lower levels of sCTLA4 mRNA and protein, and that mRNA with long (AT)n repeat alleles was more unstable. We hypothesize that the reduction in expression levels of the sCTLA4 protein caused by CTLA4 genotypes could lead to an imbalance of CD28/ CTLA4 competition on T-cell activation, and could therefore, cause the immune phenotype characteristic of UC.
We found that the allelic variations of (AT)n repeats had an influence on flCTLA4 mRNA in colonic biopsy tissues, but not on protein expression. The mechanism remains unclear, but may involve differential splicing efficiencies. The genotype-related difference in flCTLA4 protein expression may be confined to certain T-cell subpopulations. 51, 52 In recent years, CTLA4 has become a focus of research, because it is a useful therapeutic target for immunotherapy in cancer and autoimmune diseases. Abatacept (CTLA4-Ig) is a drug approved to treat rheumatoid arthritis, and ipilimumab (anti-CTLA4 antibody) is undergoing clinical trials for the treatment of melanoma and other cancers. We believe that our findings are of interest because they may provide a basis for potential trials of CTLA4-Ig as an agent of immunotherapy for UC.
In conclusion, our study establishes that (AT)n repeats carrying long alleles are highly associated with UC in consecutive sets of Han Chinese UC cases and controls in Central China. We also identified a novel single-nucleotide polymorphism (CTLA4 À1661A/G) associated with UC that potentially interacts with the long (AT)n repeats to further increase risk. We also showed that (AT)n repeats carrying long alleles are associated with decreased expression of sCTLA4 mRNA in tissue and sCTLA4 protein in the sera of UC patients. These findings may have important implications for further CTLA4 gene polymorphisms in UC Z Chen et al delineating UC pathophysiology and genetic risk, and in developing novel therapies and implementing current CTLA4-directed therapies. These CTLA4 polymorphisms and CTLA4 expression should be evaluated in other UC populations and in other immune disorders. 53 The extent of disease was defined according to the Montreal classification. 54 In all, 29 of the patients (9.7%) had extraintestinal manifestations. Arthralgia was present in 20 patients (6.7%), oral ulcer in 4 (1.3%), erythema nodosum in 3 (1.0%) and ocular disease in 2 (0.7%). A total of 63 of 300 UC patients were randomly selected for CTLA4 mRNA and protein expression analysis.
Materials and methods

Subjects
Overall, 700 age-and sex-matched, and unrelated healthy controls (mean age 46.2±13.6 years, 414 men (59.1%) and 286 women (40.9%)) were selected from the medical staff of Zhongnan Hospital of Wuhan University, as well as from healthy volunteers in the same geographic area of Wuhan city from 1 January 2005 to 30 May 2009. The healthy controls were ethnically matched and had no symptoms suggestive of chronic bowel disease and no personal or family history of UC. In all, 12 of 700 healthy controls were randomly selected for CTLA4 mRNA analysis. All study subjects provided informed consent using a study protocol approved by the ethics committee of the Wuhan University Zhongnan Hospital.
DNA isolation
A blood sample was obtained from each patient and each healthy control, and was used for DNA extraction. Genomic DNA was isolated from 5 ml EDTA-anticoagulated venous blood using conventional proteinase K digestion and phenol/chloroform extraction methods.
CTLA4 genotyping
The À1661A/G (rs4553808) and À1722T/C (rs733618) polymorphisms in the CTLA4 gene were determined by PCR-restriction fragment length polymorphism using a single primer set: forward 5 0 -CTAAGAGCATCCGCTT GCACCT-3 0 and reverse 5 0 -TTGGTGTGATGCACAGAA GCCTTTT-3 0 . 55 PCR was performed as follows: initial denaturation at 94 1C for The (AT)n repeat polymorphism (rs60872763) in the CTLA4 gene was genotyped by a semi-automatic fluorescently labeled PCR method as described previously. 33 The forward primer was labeled with 5 0 -FAM (Applied Biosystems). Primer pair sequences from 5 0 to 3 0 were forward: FAM-GCCAGTGATGCTAAAGGTTG and reverse: AACATACGTGGCTCTATGCA. 33 PCR amplification was performed in an Applied Biosystems GeneAmp PCR System PE9700: an initial denaturation at 95 1C for 10 min, followed by 35 cycles of 94 1C for 20 s, 57 1C for 20 s and 72 1C for 30 s, and final extension at 72 1C for 30 min. Genotyping was carried out on an Applied Biosystems ABI 3730 DNA Genetic Analyzer using the semi-automated GeneScan software. For each sample, 1.5 ml of the diluted PCR product was combined with 0.5 ml of internal size standard (GeneScan-500 LIZ, Applied Biosystems). The accuracy and reproducibility of automated sizing of fragments were confirmed by analysis in duplicate of randomly chosen samples (40%), which were also confirmed to have AT repeats by direct DNA sequencing on an Applied Biosystems ABI 3730 apparatus.
Colonic biopsies
Biopsy samples were collected from patients with UC undergoing diagnostic colonoscopy and from healthy controls undergoing screening colonoscopy for colorectal cancer after written informed consent. Four biopsy samples from macroscopically inflamed mucosa were collected from each UC patient: two were used for CTLA4 mRNA expression analysis and two for flCTLA4 protein analysis. Two biopsy samples from macroscopically noninflamed mucosa were collected from each UC patient and from healthy controls, and were used for CTLA4 mRNA expression analysis.
Cells and cell cultures
Peripheral blood mononuclear cell were isolated from heparinized venous blood of UC patients by density gradient centrifugation on Ficoll-Hypaque (AXIS-SHIELD, Oslo, Norway), and were suspended in RPMI 1640 medium supplemented with 10% fetal calf serum, 3 mM glutamine, 100 Units ml À1 penicillin and 100 mg ml RNA extraction and complimentary DNA synthesis Total RNA was extracted from peripheral blood mononuclear cell of patients with UC, and from fresh colonic 
56,57
Immunohistochemistry to assess flCTLA4 protein Immunohistochemical staining was performed to assess the level of flCTLA4 protein expression in biopsies of inflamed colonic tissue in UC patients using the biotin streptavidin-horseradish peroxidase method according to the manufacturer's instructions. Briefly, 5-mm-thick sections were dewaxed and incubated in 3% H 2 O 2 solution in methanol for 10 min, and then the slides were rinsed in phosphate-buffered saline. After incubation at 89 1C for 10 min in a microwave oven, and washing in phosphate-buffered saline, the sections were incubated with the mouse antihuman CTLA4 monoclonal antibody (BD Bioscience, San Jose, CA, USA) for 60 min at room temperature. The signal was detected using the antimouse Ig streptavidin-peroxidase detection kit (BD Bioscience), and counterstained with Mayer's hematoxylin according to the manufacturer's instructions and then photographed. Cells positive for flCTLA4 could be identified by brown staining.
Semi-quantitative analysis of staining intensity for the flCTLA4 protein was performed using the HPIAS-2000 image analysis software. Five highly magnified visual fields (10 Â 40 magnification) (with no overlap) from each tissue section were randomly selected. Integral optical density was automatically measured by the computer with image analysis software. The mean optical density represented the relative expression levels of flCTLA4 protein. 58, 59 Assessments were performed by two independent pathologists from Wuhan University Zhongnan Hospital, who were unaware of the CTLA4 polymorphism status.
Enzyme-linked immunosorbent assay to assess sCTLA4 protein Serum levels of sCTLA4 protein expression levels were measured in patients with active UC using Enzymelinked immunosorbent assay kits (Bender Medsystems, Vienna, Austria).
Statistical analysis
Statistical analysis was performed by SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). Comparisons of the genotype and allelic frequencies were performed using the w 2 test with Yates' correction or Fisher's exact test. OR and 95% CI were calculated for the disease in carriers of the specific alleles. Bonferroni's multiple correction was used for the P c by multiplying the P-value by the number of the statistical tests to avoid the a1 error. Multivariate analysis was estimated by logistic regression. Continuous variables were reported as means ± s.d. Statistical comparisons were performed with the two-tailed, Student's t-test and one-way ANOVA (analysis of variance) analysis. A value of Po0.05 was considered to be statistically significant.
